Delcath to trial Hepzato drug device combo in colorectal cancer

Delcath System has received clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application to start enrolment in a Phase II trial evaluating its Hepzato Kit (melphalan/hepatic delivery system) as an add-on treatment in patients with liver-dominant metastatic colorectal cancer (mCRC).